<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629057</url>
  </required_header>
  <id_info>
    <org_study_id>BNIT-PR-001</org_study_id>
    <nct_id>NCT00629057</nct_id>
  </id_info>
  <brief_title>A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer</brief_title>
  <acronym>BNIT-PR-001</acronym>
  <official_title>An Open-Label, Phase I Dose Escalation Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BNIT-PR-001 is an open-label, multi-center, Phase I dosing evaluation trial of MVA-BN®-PRO in&#xD;
      men with androgen-insensitive prostate cancer. Patients will have PSA recurrence after being&#xD;
      treated with androgen suppression therapy or complete androgen blockade.&#xD;
&#xD;
      The trial will consist of a treatment with up to 6 vaccinations with MVA-BN®-PRO at monthly&#xD;
      intervals, followed by a 1-year follow-up phase. A vaccination may be 1, 2, or 4 injections&#xD;
      of study vaccine.&#xD;
&#xD;
      The study is designed to examine safety as well as the effect of three different doses on&#xD;
      immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MVA-BN®-PRO is a candidate prostate cancer immunotherapy product comprised of a highly&#xD;
      attenuated non-replicating vaccinia virus, MVA-BN®, engineered to encode prostate specific&#xD;
      antigen (PSA) and prostate acid phosphatase (PAP) proteins. The MVA-BN®-based vaccine&#xD;
      provides innate and adaptive immune activating factors, and vaccination by this strategy will&#xD;
      be evaluated for its capacity to help override self and tumor tolerance mechanisms.&#xD;
&#xD;
      Previous work has shown PSA and PAP antigens to be immunogenic in humans when presented with&#xD;
      immune stimulatory components. Multiple clinical studies have demonstrated promising activity&#xD;
      of PSA-targeted vaccinia-based immunotherapy. Additionally, PAP-based cellular therapy&#xD;
      immunization approaches, have shown promise in Phase III clinical trials and provided for&#xD;
      enhanced survival. The strategy undertaken by BNIT is to combine both antigens in the MVA-BN®&#xD;
      vector to enhance the immunogenic effect and to help mitigate development of tumor&#xD;
      resistance.&#xD;
&#xD;
      This trial examines three vaccination regimens of MVA-BN®-PRO:&#xD;
&#xD;
      Vaccine is provided at (0.5cc/dose/1x10e8 TCID50)&#xD;
&#xD;
        -  Cohort 1: 1 sc injection every 4 weeks x 3; retreated once at the same dose and&#xD;
           schedule.&#xD;
&#xD;
        -  Cohort 2: 2 sc injections every 4 weeks x 3; retreated once at the same dose and&#xD;
           schedule.&#xD;
&#xD;
        -  Cohort 3: 4 sc injections every 4 weeks x 3; retreated once at the same dose and&#xD;
           schedule.&#xD;
&#xD;
      These dose regimens are based on the current dose of MVA-BN® (1x10e8 TCID50 by sc injection)&#xD;
      under development as a prophylactic vaccine for the prevention of smallpox, and on related&#xD;
      clinical studies of MVA-nef-based vaccines (5x10e8 TCID50) for induction of heterologous&#xD;
      immunity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single and multiple injection regimens of MVA-BN®-PRO for the treatment of androgen-insensitive prostate cancer.</measure>
    <time_frame>Continuous</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the ability of MVA-BN®-PRO to generate humoral and cellular immune responses to prostate antigens, and to define an optimal dose for future studies.</measure>
    <time_frame>Continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Androgen-insensitive Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle level dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-PRO</intervention_name>
    <description>1x10e8 TCID50 q 4 wks x 6</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-PRO</intervention_name>
    <description>2 x 10e8 TCID50 q 4 wks x 6</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-PRO</intervention_name>
    <description>4 x 10e8 TCID50 q 4 wks x 6</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Men, 18 - 75 years of age&#xD;
&#xD;
          -  Documented prostate cancer with a rising PSA post androgen suppression or blockade&#xD;
             therapy&#xD;
&#xD;
          -  Chemotherapy naïve&#xD;
&#xD;
          -  ECOG Performance Score of 0,1, or 2&#xD;
&#xD;
          -  Life expectancy ≥ 1 year&#xD;
&#xD;
          -  No significant cardiac, bone marrow, hepatic, or renal dysfunction; or coagulopathy&#xD;
             (defined as no AE ≥ Grade 3 according to NCI CTCAE v 3.0). Patients with a known&#xD;
             history of a CLINICALLY NON-SIGNIFICANT laboratory parameter may be eligible for&#xD;
             inclusion provided an exemption is granted by the study Medical Monitor prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  A negative virology screen for HIV, hepatitis B surface antigen, and hepatitis C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Congestive heart failure (NYHA Class III or IV), unstable angina, or cardiovascular&#xD;
             disease such as stroke or myocardial infarction (current or within the past 6 months)&#xD;
&#xD;
          -  History of prior malignancies other than prostate cancer within the past 5 years,&#xD;
             excluding basal or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Known allergy to eggs, egg products, or aminoglycoside antibiotics, e.g., gentamicin&#xD;
             or tobramycin&#xD;
&#xD;
          -  Chronic administration (defined as 5 or more days of consecutive use) of systemic&#xD;
             corticosteroids within 14 days of the first planned dose of MVA-BN®-PRO. Use of&#xD;
             inhaled steroids, nasal sprays, eye drops and topical creams for small body areas is&#xD;
             allowed.&#xD;
&#xD;
          -  History of or active autoimmune disease. Persons with vitiligo or thyroid disease&#xD;
             taking thyroid replacement hormones are not excluded.&#xD;
&#xD;
          -  Prior solid organ or hematopoietic allogenic transplant(s)&#xD;
&#xD;
          -  Receipt of an investigational agent within 28 days of the first planned dose of&#xD;
             MVA-BN®-PRO&#xD;
&#xD;
          -  Prior &quot;vaccine&quot; therapy for prostate cancer at any time&#xD;
&#xD;
          -  Vaccination: Live (attenuated) vaccine (e.g., FluMist®). Vaccination with a live&#xD;
             vaccine within 28 days of the first planned dose of MVA-BN®-PRO, or plans to receive a&#xD;
             live vaccine within 28 days after the last dose of MVA-BN®-PRO is not allowed&#xD;
&#xD;
          -  Vaccination: Killed (inactivated) vaccine (e.g., PneumoVax®). Vaccination with a&#xD;
             killed vaccine within 14 days of the first planned dose of MVA-BN®-PRO, or plans to&#xD;
             receive a killed vaccine within 14 days after the last dose of MVA-BN®-PRO is not&#xD;
             allowed.&#xD;
&#xD;
          -  Radiation therapy within 28 days of the first planned dose of MVA-BN®-PRO or plans for&#xD;
             radiation therapy during treatment or re-treatment. Prior to initiating palliative&#xD;
             radiation during the (re)treatment phase of the study, the Sponsor's medical monitor&#xD;
             or designee must be notified.&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, would prevent full&#xD;
             participation in this trial (including the long-term follow-up), or would interfere&#xD;
             with the evaluation of the trial endpoints&#xD;
&#xD;
          -  Study personnel&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Bandman</last_name>
    <role>Study Director</role>
    <affiliation>Bavarian Nordic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital Center for Cancer Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of South Texas</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>androgen-insensitive, non-metastatic, prostate, cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

